US Patent

US12357636 — Vibegron for the treatment of overactive bladder symptoms

Method of Use · Assigned to Urovant Sciences GmbH · Expires 2042-07-06 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia by orally administering 60-90 mg of vibegron per day.

USPTO Abstract

The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.

Drugs covered by this patent

vibegron (VIBEGRON)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4219`	—	vibegron

Patent Metadata

Patent number: US12357636
Jurisdiction: US
Classification: Method of Use
Expires: 2042-07-06
Drug substance claim: No
Drug product claim: No
Assignee: Urovant Sciences GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.